Candel Therapeutics outlines prostate cancer pipeline at Canaccord conference

Candel Therapeutics Inc. outlined its pipeline of investigational therapies and clinical progress in prostate cancer during a presentation at the Canaccord Genuity Growth Conference on Tuesday.

The biotechnology firm, which focuses on developing off-the-shelf, non-personalized cancer immunotherapies, emphasized its lead candidate, CAN-3110, in the context of prostate cancer treatment. CAN-3110 is an oncolytic virus therapy designed to selectively replicate within and destroy cancer cells while stimulating an immune response.

During the conference, Candel provided updates on the ongoing clinical trials for CAN-3110, including its Phase 1b/2 trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The company highlighted preliminary safety and efficacy data from the trial, noting that CAN-3110 has demonstrated a favorable tolerability profile and encouraging signs of biological activity in early-stage evaluations.

Candel also discussed its broader pipeline, which includes additional oncolytic virus candidates targeting other solid tumors, though prostate cancer remains a primary focus. The company reiterated its commitment to advancing these therapies through clinical development, with the goal of addressing unmet medical needs in oncology.

Investor interest in Candel’s pipeline has grown amid increasing attention to novel immunotherapies in oncology. The presentation at Canaccord Genuity’s conference follows recent regulatory and clinical milestones for the company, including interactions with the U.S. Food and Drug Administration regarding trial design and patient enrollment strategies.